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Pulse Wave Analysis in the first trimester of pregnancy: a possible predictive test 
to identify women at risk of placental or maternal preeclampsia and IUGR 
Background:  
Preeclampsia and intrauterine growth restriction are major contributors to maternal 
and/or perinatal mortality and morbidity worldwide. At present preeclampsia is 
classified based on time domain. Just few Authors proposed classification based on 
different origin of the diseases: placental and maternal. The former involves inadequate 
placentation and consequently placental insufficiency and IUGR; the latter is thought to 
be caused by maternal "metabolic syndrome" characterized by low grade chronic 
inflammation and android obesity, but associated with normal placental function and 
appropriate fetal growth (AGA).  
Independently on the classification of the disease, it is well known that women with a 
history of preeclampsia are at increased risk of cardiovascular events later on in life.  
Recent developments in cardiological technology provided useful non-invasive tool 
capable to assess peripheral and central vascular resistance: applanation tonometry. By 
assessing the radial pulse wave it is possible to derive indices of arterial stiffness 
(Augmentation Index) and compliance (Pulse Way Analysis and Pulse Way Velocity). 
In the literature there are few studies that investigated arterial stiffness in preeclamptic 
women, but limited mostly by low study population. Just one report investigated 
applanation tonometry in the first trimester of pregnancy. None of Authors explored the 
role of pulse wave analysis considering the above proposed classification of 
preeclampsia. 
Aim: to investigate maternal indices of central and peripheral vascular resistance 
(arterial stiffness) and indices of central pressure in aorta, in the first trimester of 
pregnancy, in preeclampsia of maternal and placental origin and fetal growth restriction. 
Methods: applanation radial tonometry together with uterine artery Doppler have been 
performed between 11-13+6 wg in general population attending to our hospital for 
Down syndrome screening. Augmentation index corrected for heart rate (AIX75) and 
Aortic systolic peak have been calculated. PE was defined as placental when associated 
with IUGR and of maternal origin in cases with clinical manifestation of 
hypertension/PE but with appropriate fetal growth, independently of time of onset. 
Results: 308 pregnancies were recruited: four (1%) developed PE/IUGR; four (1%) 
PE/AGA; seven (2,3%) GH; 16 (5,2%) IUGR, and eight (2,6%) SGA. None of the 
seven women with gestational hypertension had associated fetal growth restriction, so 
they were included in maternal preeclampsia group (PE+AGA).  
Patients with maternal PE showed a statistically higher BMI and higher rate of IVF 
pregnancy when compared to controls (p=0,011), while placental PE showed a higher 
incidence of previous pregnancy affected by preeclampsia (p=0,004). There were no 
statistical differences for other demographic data.  
Both maternal and placental PE group delivered at an earlier GA, but only placental PE 
had smaller babies and major incidence of admittance to NICU (p< 0,001). There were 
no significant differences in heart rate and Augmentation index at 75 bpm between the 
two groups of PE compared with controls. Mean arterial pressure was significantly 
higher in both placental and maternal preeclampsia when compared to the control 
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group, while central systolic pressure was significantly higher only in placental PE 
group (p< 0,001). 
The mean uterine artery PI was significantly higher in placental PE group (p< 0,001) 
and maternal serum PAPP-A resulted significantly lower only in maternal PE group 
(p=0,024). 
 
Conclusions:  
Although, the classification of preeclampsia based on time domain, at the moment the 
most used, brought to some improvements in terms of biochemical and biophysical tests 
prediction, at present is still not able to fulfill all diagnostic and preventive needs. 
Indeed, despite all scientific effort for the past three decades, at the present there does 
not exist universally recognized screening test of any kind capable to predict 
preeclampsia or IUGR and the severity of the disease.  
With this pilot study, we wanted to investigate the characteristics of preeclampsia of 
maternal and placental origin and pregnancies with fetal growth restriction in terms of 
peripheral and central vascular resistance by applanation tonometry in the first trimester 
of pregnancy. Due to the smallness of the cohort, we did not try to assess the prediction 
of the test. Nevertheless, the newness of our work stand in the understanding of the 
underlying physiopathology of preeclampsia. 
Our data confirmed the hypothesis regarding different origin of PE: indeed, in PE of 
maternal origin we found the highest BMI and the highest percentage of IVF-
pregnancies. Both this factors are well known to correlate to metabolic syndrome, low 
grade chronic inflammation and insulin resistance. 
Conversely, in PE of placental origin we found the highest number of women with 
reoccurrence of preeclampsia that supports the immunological/genetic hypothesis that 
causes inadequate placentation. This hypothesis is supported also by the observation 
that women with preeclampsia of placental origin present significantly higher mean 
uterine artery PI, sign of an impaired placentation as soon as in the first trimester of 
pregnancy. 
As it concern the hemodynamic parameters, in accordance to the literature, we found 
the mean arterial pressure significantly higher in both preeclampsia of placental and 
maternal origin when compared to the control group. Interestingly, the central pressure, 
both systolic and diastolic, was significantly higher only in placental PE group 
suggesting lower central vascular compliance in women with inadequate placentation. 
This could suggest a different and more severe physiopatological pathway at the basis 
of preeclampsia of placental origin when compared to maternal one. 
Several Authors found increased values of augmentation index in women with 
preeclampsia (more pronounced in early and less important in late PE) at the time of 
onset of the disease. Conversely, we found no significant differences in Augmentation 
index at 75 bpm between groups, suggesting that in the first trimester the biochemical 
and hormonal modifications still does not reflect on peripheral vascular resistance both 
in preeclampsia of maternal and placental origin. 
In conclusion, we found that the classification of preeclampsia based on its origin, 
maternal and placental, is supported by the demographic data. Our data suggest that, as 
soon as in first trimester, for arterial mean pressure been equal in both women that will 
develop PE of maternal and placental origin, and higher in respect to controls, only PE 
of placental origin presents higher central pressure. Nevertheless, no differences were 
found for wave reflection, suggesting later development of the peripheral vascular 
alteration.  
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INTRODUCTION 
 
Definition, etiology, physiopathology, diagnosis and clinical 
manifestation of Preeclampsia and IUGR 
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major 
contributors to perinatal mortality and morbidity [1]. Affecting more than 
half a million pregnancies delivered in the United States alone, these 
pregnancy complications not only alter the immediate outcomes of 
pregnancy at the time of delivery but also the long-term cardiovascular 
health of the affected women and children. For example, a history of 
preeclampsia increases a female’s risk of myocardial infarction, stroke or 
diabetes mellitus by two to eight folds over the next two decades [2].  
Moreover, newborns diagnosed with IUGR at birth have a two to eightfold 
increased risk for hypertension, cardiovascular disease, diabetes mellitus or 
renal disease as adults [3,4].  
 
Preeclampsia 
Preeclampsia is a newly onset hypertension in previously normotensive 
women coupled with elevated urine protein in women without previous 
kidney failure, developed after 20 weeks of gestation, as defined by the 
International Society for the Study of Hypertension in Pregnancy (ISSHP) 
[5-8]. The syndrome can be exacerbated to severe hypertension and 
proteinuria (“severe preeclampsia”) that can lead to eclampsia, an obstetric 
emergency associated with brain convulsions, cerebral edema and stroke, a 
life threatening condition for the mother and her baby [9]. HELLP 
(hemolysis, elevated liver enzymes, low platelets) syndrome may correlate 
to severe preeclampsia and is characterized by elevated liver enzyme 
activities and reduced numbers of platelets indicating injury to the liver, 
blood system and potentially other organs. The HELLP syndrome occurs 
primarily in white, multiparous women above the age of 25 years [10,11].  
Preeclampsia affects 2–8% of all pregnant women and it is the second 
cause of maternal death during pregnancy, comprising 18% of pregnancy-
associated maternal mortality worldwide [12,13]. According to the 
National Institute of Child Health and Human Development (NICHD) [14], 
confirmed by a large scale studies of the Maternal-Fetal Medicine 
Foundation [15] and other international surveys [16], 25–27% of 
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preeclamptic patients deliver prematurely (before 37 weeks of gestation 
and approximately 10% before 34 weeks), and the earliest the delivery 
occurs the most severe are the complications for both the mother and the 
baby. Approximately 90% of early preeclamptic patients (cases with 
severity requiring delivery before 34 weeks), and more than 50% of 
preterm preeclamptic patients require a cesarean section compared with 
approximately 30% in preeclampsia at term and 15–18% in the unaffected 
population [16-19]. Studies have revealed that although preterm 
preeclampsia affects only about 1/4 of all preeclampsia cases (1–2% of the 
entire pregnancy population in Canada, Netherlands, Denmark, Finland, 
USA and 0.7% in UK), the frequency of eclampsia, stroke, cerebral 
vascular accident and other severe complications in this sub-group of 
preeclampsia is higher compared to term preeclampsia. More than 75% of 
babies born from early preeclampsia (<34 weeks) and over 50% of those 
born preterm (34–37 weeks) are either small for gestational age (SGA) or 
show IUGR. Newborns of early preeclampsia account for the major 
fraction of intra-partum and post partum death, cerebral palsy, blindness 
and motor and cognitive disorders. These complications are less severe in 
term preeclampsia [20-26]. 
This definition of preeclampsia is based on clinical manifestations of the 
disease, but the knowledge about the pathogenesis and etiology is still 
unclear. Extensive research in the last 15 years has demonstrated that 
preeclampsia is characterized by abnormal vascular response to 
placentation that is associated with increased systemic vascular resistance, 
enhanced platelet aggregation, activation of the coagulation system and 
endothelial cell dysfunction, when there is a wrong recognition of immune 
system [27]. The opinion was that the clinical findings of preeclampsia 
could manifest as either a maternal syndrome (hypertension and proteinuria 
with or without other multisystem abnormalities) or fetal syndrome (fetal 
growth restriction, reduced amniotic fluid, and abnormal oxygenation) [27-
29]. 
Over the past decade, the knowledge about preeclampsia has changed 
significantly by virtue of increased recognition of the heterogeneous nature 
of this syndrome. The physicians observed that the manifestations of 
preeclampsia can develop before than 34 weeks (early onset) or after 34 
weeks (late onset), during labor, or postpartum. They suggested that early 
and late onset preeclampsia could have different etiologies and should be 
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regarded as different forms of the disease [29,30]. Early onset preeclampsia 
was commonly associated with abnormal uterine artery Doppler, fetal 
growth restriction, evidence of ischemic lesions on placental examination 
and adverse maternal and neonatal outcomes. Whereas late onset 
preeclampsia was mostly associated with normal or slight increased uterine 
resistance index, a low rate of fetal involvement and more favorable 
perinatal outcomes [16,31-33]. Furthermore, they observed that pregnancy 
is characterized by certain structural and functional changes in the 
cardiovascular systems that are necessary to accommodate the growing 
demands of the fetus and placenta. Adequate cardiovascular adaptation 
during early pregnancy leads to a state of high blood flow and low vascular 
resistance, which is a prerequisite to successful pregnancy outcome. In 
contrast, inadequate or excessive cardiovascular adaptation before 20 
weeks gestation is associated with pregnancies complicated by gestational 
hypertension, preeclampsia, IUGR or a combination of these [33,34]. 
In 2008, Valensise [35] observed two different groups of women that 
subsequently develop early or late preeclampsia. Patients with early onset 
preeclampsia had significantly higher rates of advanced maternal age and 
bilateral uterine arteries notching and lower gestational age at delivery and 
lower neonatal weight centile compared to both control and late 
preeclampsia groups. In contrast, patients with late onset preeclampsia had 
higher body mass index compared to the other two groups. 
Moreover he proposed that early and late onset preeclampsia develop from 
two distinct hemodynamic states: patients with early preeclampsia had 
significantly high total vascular resistance and lower cardiac output 
compared to those with late preeclampsia that present low vascular 
resistance and high cardiac output. 
The author concludes that early preeclampsia appears to be more related to 
the evolution of an extremely altered cardiovascular response probably 
triggered by a placental disorder; instead, late preeclampsia seems to be 
more linked to maternal constitutional factors. 
Two years before Redman [36] wrote an article about the different kind of 
inflammation in preeclampsia and he suggested that the disease constitutes 
a spectrum that includes so-called ‘maternal’ and ‘placental’ preeclampsia. 
Redman supports the theory that consider placental preeclampsia as an 
abnormal placenta in a normal woman, and the maternal preeclampsia as a 
normal placenta within a woman who suffers from a preexisting problem, 
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such as obesity, cardiovascular disease or diabetes. Consequently, the 
pregnancy become a systemic inflammatory stress for women, particularly 
during the second half of gestation, to which both endocrine and placental 
factors contribute. The placental stimulus may comprise debris released 
into the maternal circulation from the syncytiotrophoblast, signaling danger 
to the maternal innate immune system. Preeclampsia ensues when the 
threshold for sustaining homeostasis is reached and excessive involvement 
of maternal endothelial integrity occurs. Many, but not all, cases of 
preeclampsia are associated with poor placentation. This comprises the first 
stage, which appears to involve decidual immune responses. Second stage 
responses are secondary to the systemic inflammatory response, which 
could explain why women bearing pregnancies with unusually large 
placentas (an excessively large inflammatory stimulus) are susceptible to 
preeclampsia. In contrast in obese women, chronic inflammation 
contributes to preeclampsia superimposed on the added stimulus from a 
normal pregnancy.  
Summarizing, placental preeclampsia is caused by an inadequate 
trophoblastic invasion of the maternal spiral arteries, that cause first a local 
inflammatory process and later a systemic inflammation which has been 
documented by altered Doppler ultrasound of uterine arteries and often 
associated with a higher incidence of fetal growth restriction. Its 
hemodynamic system is characterized by low cardiac output and high total 
vascular resistance.  
Conversely, maternal preeclampsia is associated with normal placentation 
and fetal growth and is thought to be a manifestation of an underlying 
metabolic disorder with chronic inflammatory state and hemodynamic 
system characterized by high cardiac output and low total vascular 
resistance. 
Therefore, actually there is an evidence that preeclampsia is an 
heterogeneous condition with early disease, thought to be a consequence of 
impaired placentation [37-39], whereas in late preeclampsia the main 
pathophysiological processes resemble those of the metabolic syndrome 
with increased insulin resistance [40-43].  
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IUGR 
Occasionally, severe placental disease can result in IUGR without evidence 
of preeclamptic manifestations or maternal endothelial dysfunction.  
In the group of fetuses with a decrease of growth we can classify IUGR and 
fetuses small for gestational age.  
Intrauterine growth restriction refers to a condition in which a fetus is 
unable to achieve its genetically determined potential size. This functional 
definition seeks to identify a population of fetuses at risk for modifiable but 
otherwise poor outcomes. 
IUGR is defined by the coexistence of abdominal circumference (AC) 
below the 5th percentile for local standards (or a decrease of AC percentile 
>40 percentile from mid trimester to third trimester) [44] and an abnormal 
uterine Doppler waveform according local standards [45]. Growth 
retardation is also confirmed at delivery against the standards of weight for 
gestational age population reference.  
The etiology of IUGR is an impaired placentation as described above and 
this etiology explain the asymmetrical growth restriction and altered 
Doppler velocimetry of uterine artery and consequently of umbilical artery. 
Conversely, SGA fetuses are defined as constitutionally smaller for 
gestational age and presenting a weight at birth below the 10th percentile 
for the gestational age population reference. This group presents normal 
uterine and umbilical artery Doppler and usually a symmetrical growth 
restriction and better outcome. 
The differentiation between SGA and IUGR fetuses during prenatal life is 
not always simple and clear. 
In fact, there is some confusion in terminology for the lack of uniform 
diagnostic criteria. Furthermore almost of authors use the terms small for 
gestational age and intrauterine growth restriction as synonymous. Others 
authors think that the term SGA is more appropriate referring to infant 
while IUGR referring to fetus. By definition, 10% of people in any 
population have a weights, as well as heights, below the 10th percentile. 
This is the cut-off value mainly used for defining the IUGR. A minority of 
authors define the cut-off value at the 5th or at 3th percentile. There are 
many evidence demonstrating that the adverse perinatal outcome are 
mainly confined to infants below the 5th or 3th percentile [46].  
It is very important specify that fetal growth depends by two broad and 
overlapping stages during the pregnancy. 
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During the first period the growth is characterized as a germinal and 
embryonic period while during the last period there is a differentiation’s 
prevalence depending by genetical characteristics. This is the reason 
because there is less biologic variability in growth during the first period of 
pregnancy. On the contrary, there is an increasing variability during the 
pregnancy progress. Therefore, also the placenta effects are more evident in 
the third trimester of pregnancy when the fetus need more nutriments. 
It has been suggested that these variable presentations of growth should be 
regarded distinct disease entities in etiology and in abnormal placentation 
[33,47]. 
For this reason in the last years the physicians had proposed the hypothesis 
of a different etiology of IUGR, according to its age of onset: early and 
late. The early onset cases are caused by an impaired placentation during 
the first trimester, while for late onset cases there are placental 
abnormalities that have arisen late in women with pre-existent diseases. 
Therefore, the fetuses with growth restriction are an heterogeneous group 
with etiology and pathophysiology still unclear. Maybe the early IUGR can 
derive from an abnormal placentation and late IUGR from a backward 
different placental alteration in women who had metabolic syndrome. 
 
Prevention of Preeclampsia and IUGR 
The primary prevention of any preeclampsia or IUGR remains a 
considerable challenge in obstetrics. Although the symptoms of 
preeclampsia and IUGR generally manifest in the second to third trimester 
of pregnancy, their underlying pathology takes place in the first trimester 
[45]. 
It is the assumption taken by many researchers and physicians that 
identifying a woman at risk for preeclampsia or IUGR may help managing 
her risk and potentially use several promising prophylactics to improve her 
outcomes [12]. 
Today it is a standard practice in perinatology to evaluate a woman’s prior 
risk based on previous medical, obstetric and demographic questions 
characterized by relatively low sensitivity and specificity. Thus, for women 
considered at high risk for preeclampsia, due to previous preeclampsia or 
chronic hypertension or diabetes or multi-fetal pregnancy, the frequency of 
those who will develop preeclampsia is 19% (previous preeclampsia), 22% 
(diabetes) and 25% (chronic hypertension) [48]. 
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About IUGR, maternal smoking, low educational level, advanced maternal 
age and black race are associated with increased risk of the pathology [49]. 
The same is the case for maternal medical conditions like gestational 
hypertensive disorders, pre and gestational diabetes, systemic lupus 
erythematosus, chronic renal disease, and thyroid disorders [50]. Finally, 
there is a strong association between IUGR and prior pregnacy with a 
growth restricted fetus. 
Furthermore, nulliparity is one of the major clinical risk factor for the 
development of preeclampsia and IUGR [51]. Although the screening by 
maternal history alone will detect only 30% of women who will have 
preeclampsia [39], the clinical risk-based strategy is not effective for 
nulliparous women without other risk factors. 
Estimating each woman’s individual risk would allow appropriate antenatal 
surveillance, and would also enable to test preventive strategies such as 
low-dose aspirin in selected high-risk groups [52]. However, the use of 
prophylactic treatments is likely to be more beneficial when started earlier 
in pregnancy, ideally before 16 weeks [53]. It would be thus important to 
develop an effective method of early identification of high risk groups.  
To improve the prediction of the disease, many authors have combined 
patient history with a series of biophysical and biochemical markers that 
change from as early as the first trimester of pregnancy in cases that 
subsequently develop preeclampsia or IUGR. Studied biophysical markers 
include mean arterial blood pressure [54], uterine artery Doppler [55,56] 
and more complex evaluations such as maternal cardiac output [57], brain 
hemodynamic measurements [58] and more recently pulse wave analysis 
[59]. Several biochemical markers have been tested for the prediction of 
preeclampsia and IUGR, including products of fetal and placental origin, 
markers of renal or endothelial damage, angiogenic and antiangiogenic 
factors, and markers of oxidative stress as reviewed by Giguère et al. in 
2011 [60].  
Currently, clinical history, maternal serum biochemistry and uterine artery 
Doppler sonography before 14 weeks have been investigated, even though 
with limited success[39,61-63]. In the second trimester, uterine artery 
Doppler can claim a detection rate of only 63.1% for a high (25%) false-
positive rate [64] for preeclampsia and only 20% for IUGR [65] . First-
trimester uterine artery Doppler studies have been shown to have high 
sensitivity but poor specificity, with a high FPR [66]. The combination of 
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first-trimester uterine artery Doppler indices and placental protein 13 
(PP13) holds promise in this respect, but further evidence is needed [61]. 
Maternal serum markers, such as inhibin A, activin A, soluble fms-like 
tyrosine kinase 1 (sFlt-1) and soluble endoglin, when used alone are proved 
poor predictors of preeclampsia [67-69].  
A systematic review of screening tests for preeclampsia concluded that no 
single test is yet available to provide a good diagnostic accuracy [12]. A 
combined screening involving several relevant markers is more likely to 
provide the best prediction.  
First-trimester screening would represent a major advantage over a second-
trimester approach because it opens prospects for early and more efficient 
interventions.  
 
Pulse wave analysis 
In the latest years the physician’s attention was posed on the hemodynamic 
changes in preeclamptic women.  
In women affected by preeclampsia, the normal maternal cardiovascular 
adaptation, characterized by increased intravascular volume, cardiac 
output, heart rate (HR), aortic distensibility, compliance and by a marked 
decrease in vascular resistance [70-72], fails [73]. Several studies, using 
two-dimensional echocardiography, have confirmed that preeclampsia is 
characterized by a marked reduction of the maternal cardiac output and an 
increase of peripheral resistance [73-75].  
Despite the extensive number of studies in the maternal hemodynamic 
adaptation during preeclampsia, the available information on maternal 
central hemodynamics, wave reflection, and arterial stiffness, in this 
condition, is however scarce. 
In non-pregnant subjects, examination of the characteristics of the 
peripheral and central arteries provides valuable information about the 
circulatory changes associated with hypertension and/or vascular disease 
[76,77].  
Outside pregnancy, arterial stiffness has been shown to be increased in 
hypertensive patients, using a variety of methods such as Doppler color 
echocardiography [78] and pulse wave velocity [77,79,80-83]. Another 
technique, pulse wave analysis, the noninvasive analysis of the aortic 
pressure waveform and aortic stiffness, is possible by the simple, validated, 
and reproducible technique of applanation tonometry [84-90]. Pulse wave 
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analysis has been widely studied in the general population [84-90] and can 
quantify alterations in vascular compliance associated with conditions that 
cause endothelial dysfunction, such as diabetes, renal disease, and 
arteriosclerosis. Central pressures may be more relevant than brachial 
artery blood pressure to cardiovascular pathophysiology; for example, 
central pulse pressure is a better predictor of cardiovascular events than is 
brachial blood pressure [91,92].  
Studies in nonpregnant women have found differential effects of 
antihypertensive drugs on central hemodynamics, despite similar effects on 
peripheral blood pressure measurements [93-95]. These findings have 
contributed to a major change in the guidelines on the management of 
hypertension outside pregnancy.  
Moreover, the arterial stiffness is an independent predictor of 
cardiovascular events and mortality even in healthy subjects [96]. 
Interestingly, women with a history of preeclampsia are also at increased 
risk of cardiovascular events later on in life [97], and this association may 
be mediated by an increased arterial stiffness. 
In pregnancies with preeclampsia, there is some evidence that in addition to 
the vascular changes in the uteroplacental unit there is a generalized 
increase in maternal arterial stiffness [98-103].  
Normal values for pulse wave analysis in uncomplicated pregnancies have 
recently been established [99]. Three studies using pulse wave analysis 
[101,103,104] showed that arterial stiffness is increased in women with 
hypertensive disorders of pregnancy compared with normotensive pregnant 
women.  
Recent studies using PWA have confirmed a reduced arterial compliance 
(in other words, increased arterial stiffness) in women with clinically 
established preeclampsia [99,101,103].  
Only one study is done in the first trimester of pregnancy and it supposed 
that PWA could predict preeclampsia and it could be used like a screening 
test [105]. 
Data respect to maternal vascular function regarding women with a history 
of a normotensive IUGR pregnancy, are currently limited and inconsistent. 
Only one article by Elvan-Taspinar [106] underlined as an increased in 
arterial stiffness, in normotensive pregnancy, is associated with a decrease 
in birth weight centile and catch up growth after birth, independently from 
mean arterial pressure.  
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Basis of PWA phisiology  
Each heartbeat generates a pulse wave that travels away from the heart and 
is reflected back at the areas of high resistance. The reflected wave travels 
back towards the heart and meets the advancing wave, augmenting its 
height. Generally, the reflected wave reaches the aorta during diastole, 
enhancing the cardiac perfusion. When arterial stiffness is increased, the 
arterial pulse wave travels faster, so the reflected wave reaches advancing 
wave in the systole, resulting in significant augmentation of the systolic 
peak. This can be measured as increased augmentation index. Interrogation 
of the radial artery waveform (pulse wave analysis of the radial artery) can 
provide information on augmentation index and the central, aortic 
haemodynamics [77,81,107].  
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Fig. 1. A.Typical ascending aortic pulse waveform, showing two systolic 
peaks (P1 and P2). Augmentation index is calculated as the difference 
between P2 and P1 (∆P), expressed as percentage of pulse pressure. The 
designation P1 is the first inflection point; P2 is the second inflection point. 
B. In hypertensive disorders, arterial wall stiffness is increased; the arterial 
pulse wave travels faster, so the reflected wave reaches the advancing wave 
in systole, resulting in greater augmentation of the systolic peak. Time tr is 
the time to reach the reflected wave. 
Khalil. Antihypertensives and Pulse Wave Analysis. Obstet Gynecol 2009. 
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STATE OF THE ART 
 
Preeclampsia and intrauterine growth restriction are major contributors to 
maternal and/or perinatal mortality and morbidity worldwide. Despite 
improvement in the understanding of the pathophysiology of these 
conditions, ability to accurately predict pregnant woman who will develop 
PE and/or IUGR is limited. This greatly impairs the development and 
testing of preventive interventions.  
While different measures of placental dysfunction have been associated 
with increased risk for adverse pregnancy outcomes, the ability of any 
single indicator to accurately predict these outcomes is poor. Developing 
predictive tests is further challenged by difficulty in the timing of the 
measurements, as both the structural and biochemical characteristics of the 
placenta change with gestational age. The ideal screening test would 
accurately predict the development of adverse pregnancy outcomes early 
enough to provide a window for preventive interventions.  
Over the past decade, the knowledge about preeclampsia has changed 
significantly by virtue of increased recognition of the heterogeneous nature 
of this syndrome. 
The definition of preeclampsia, based on clinical manifestations of the 
disease or based on the time domain onset of the disease, does not consider 
the etiology of this pathological syndrome.  
Actually, there is an evidence that preeclampsia is an heterogeneous 
condition with two different clinical scenarios: the first one, typically, with 
early onset (< 34 weeks) associated with fetal growth restriction, alteration 
of placental and fetal Doppler velocimetry and important maternal 
involvement, thought to be a consequence of impaired placentation; the 
second one, mainly with late onset normal fetal growth, normal feto-
placental blood flow and rarely with important clinical involvement for the 
mother. The underlying pathophysiological process to this conditionis 
thought to be the metabolic syndrome with chronic low-grade inflammation 
and increased insulin resistance characterizing typically women with 
android obesity. 
This is the rationale to support the theory that stress mainly the etiology of 
the disease, and that considers preeclampsia of placental origin associated 
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with growth restricted fetus (IUGR), while preeclampsia of maternal origin 
associated with appropriately growth fetus (AGA). 
It is well known that women with a history of preeclampsia are at increased 
risk of cardiovascular events later on in life.  
Improvements in non-invasive technology, as applanation tonometry, 
provided useful novel tool to assess peripheral and central vascular 
resistance. The arterial stiffness is an independent predictor of 
cardiovascular events and mortality even in healthy subjects. Recent 
studies using Pulse Way Analysis confirmed a reduced arterial compliance 
(in other words, increased arterial stiffness) in women with clinically 
established preeclampsia [99-103]. 
Only one study was performed in the first trimester of pregnancy stating 
that PWA was a good predictor of early preeclampsia and, therefore, 
potentially could be used as screening test [105]. 
Data regarding maternal vascular function in women with a history of a 
normotensive IUGR pregnancy, are currently limited. Only one article by 
Elvan-Taspinar found an increased arterial stiffness, in normotensive 
pregnancy, to be associated with a lower birth weight centile and decreased 
catch up growth after birth, independently from mean arterial pressure 
[106].  
Most of the studies are limited by the small cohort, and none considered 
preeclampsia divided by the underlying etiology. 
 
AIM OF THE STUDY 
 
The aim of the study is to investigate maternal indices of central and 
peripheral vascular resistance (arterial stiffness) and indices of central 
pressure in aorta, in the first trimester of pregnancy, in preeclampsia of 
maternal and placental origin and fetal growth restriction. 
 
MATHERIAL AND METHODS 
 
This is a prospective longitudinal cohort study offered to pregnant women 
at the time of screening for Down syndrome at 11 to 13+6 weeks, between 
January 2011 and December 2011, in the Maternal Fetal Medicine Unit, 
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Department of Obstetrics and Gynecology, Buzzi Children’s Hospital, 
University of Milan.  
The study was approved by Ethics Committee of Istituti Clinici di 
Perfezionamento (ICP)-Buzzi Children’s Hospital (CE approval 277/2011). 
Written informed consent was obtained from all women before the 
enrollment. At the time of inclusion, women had an interview with a 
researcher and answered a standardized questionnaire on maternal 
characteristics and medical history. Demographic and clinical data 
included: age, racial origin (Caucasian, African, Asian, East Asian and 
Mixed), smoking habit, family history of hypertension, medical 
pathologies, drug assumption, parity (parous or nulliparous if no delivery 
beyond 20 weeks), method of conception (spontaneous or IVF), obstetrical 
history.  
The maternal weight and height were measured and the body mass index 
(BMI) was calculated. 
The inclusion criteria were: 
• single pregnancy; 
• absence of fetal anomalies; 
• age major to 18; 
• obtained informed consent; 
The exclusion criteria were: 
• multiple pregnancy; 
• presence of fetal anomalies; 
• miscarriage before 20 weeks; 
• age inferior to 18; 
• informed consent not obtained. 
Routine risk assessment for chromosomal aneuploidies included the 
measurement of the fetal crown-rump length (CRL), nuchal translucency, 
and ultrasound screening for major fetal abnormalities. Maternal serum 
PAPP-A and free β Human Chorionic Gonadotropin were determined to 
calculate the combined patient-specific risk for trisomy 18 and 21 
[108,109]. 
During the ultrasound examination, Doppler velocimetry of uterine arteries 
(left and right) was performed. All indices were recorded: Pulsatility Index 
(PI), Resistant Index (RI), Peak Systolic Velocity (PSV). For the purposes 
of this study the mean value of the pulsatility index from the left and right 
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uterine artery was used (Mean UtA PI) [39]. Brachial blood pressure was 
measured by an aneroid sphygmomanometer, while central blood pressure 
and pulse wave reflection was assessed by applanation tonometer. 
 
Uterine arteries Doppler velocimetry assessment 
Both uterine arteries were examined as suggested by the Fetal Medicine 
Foundation, London, UK (www.fetalmedicine.com/fmf) by an operator 
certified by the Fetal Medicine Foundation (DD, GP, TS) for the first 
trimester screening with at least 3 years of experience in Doppler 
ultrasonography. A sagittal section of the uterus was obtained and the 
cervical canal and internal cervical os identified. The transducer was tilted 
from side to side and color flow mapping was used to identify each uterine 
artery along the side of the cervix and uterus at the level of the internal os. 
Pulsed wave Doppler was used with the sampling gate set at 2mm to cover 
the whole vessel and with care taken to ensure that the angle of insonation 
was less than 30°. When three similar consecutive waveforms were 
obtained the uterine artery PI was measured and the mean UtA PI was 
determined. The treating physicians were blinded for the first trimester 
Doppler results, which were not shown in the ultrasound report. Mean PI 
has been registered and classified in normal or pathological, accordingly if 
lower or higher to 2,3 PI limit value (95° percentile) [110]. 
 
Laboratory technique 
Once the ultrasound examination was performed and the gestational age 
confirmed, a blood sample (around 5 cc) was taken from each woman. 
Maternal serum PAPP-A was measured using a kit for B.R.A.H.M.S 
KRYPTOR automated immunofluorescent assays (Hennigsdorf, Germany; 
www.kryptor.net). Samples were measured within two hours. 
 
Blood pressure (BP) 
Peripheral blood pressure was measured from the right arm, after at least 5 
minutes of rest, using an aneroid sphygmomanometer. During the 
measurement the patient did not move or speak. Auscultatory Riva-Rocci-
Korotkoff measurements were performed. Brachial systolic BP was defined 
by the first Korotkoff sound and brachial diastolic BP was defined by the 
fifth Korotkoff sound.  
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Applanation tonometry and Pulse wave analysis (PWA) 
The applanation tonometry (Sphygmocor® system Atcor Medical, West 
Ryde, Australia) was performed as follows: the radial artery was gently 
compressed with the tip of the tonometer at the site of maximal pulsation. 
The tonometer contains a micromanometer (Millar Instruments, Houston, 
TX, USA) that provides very accurate recording of the pressure within the 
radial artery [82]. A generalised transfer function was applied to the radial 
artery waveform to derive the aortic pressure waveform [107,111,112]. 
From the aortic pressure waveform, the augmentation pressure (AP) and 
augmentation index (AIx) were calculated. The AP is defined as the height 
of the late systolic peak above the inflection point on the waveform.  
The AIx is defined as AP expressed as a percentage of the aortic pulse 
pressure (PP=systolic pressure minus diastolic pressure) [76,77].  
AIx is affected by changes in the heart rate. An increase in heart rate 
shortens the duration of systole. As a result, the reflected wave reaches the 
advancing wave in diastole (rather than the usual systole), resulting in 
reduced augmentation of the advancing wave, that is reduced AIx. As there 
is a linear relationship between maternal heart rate and AIx, the AIx was 
standardized to a heart rate of 75 beats per minute (AIx-75) [113]. 
The Sphygmocor system [77] was used for the analysis of the radial 
pressure wave contour. All measurements were made by six observers (SZ, 
ER, GC, VS, CM, DC). Prior to commencing the study, there was an initial 
learning period of repeated measurements until satisfactory reproducibility 
was achieved. Moreover, the Sphygmocor software has incorporated a 
quality control feature that is displayed on the screen and only recordings 
with success rate equal or higher to 85% were used. Ten sequential pulse 
wave forms were recorded, and the average peripheral and derived aortic 
waveform were generated and analyzed. The following hemodynamic data 
were derived from the recorded radial and the reconstructed central pressure 
waveform: 
•  with an integrated software Augmentation index was determined, a 
composite measure of systemic arterial stiffness and wave reflection 
amplitude; 
• aortic waveform with central systolic and diastolic pulse pressure.  
All acquired data were hided to the patients or their doctors and, therefore, 
did not influence in any way subsequent management of the pregnancy. 
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Outcome data collection 
Pregnancy outcome data were collected as follows: fetal and maternal 
outcomes were obtained either directly from the clinical record if the 
delivery occurred in Buzzi Hospital or by a telephone interview. 
 
Definition of outcomes 
The diagnosis of GH and PE was made according to the criteria of the 
International Society for the Study of Hypertension in Pregnancy [8]. 
Under this classification, GH was defined as diastolic blood pressure above 
90 mm Hg or more on at least two occasions, at 4 hours apart, developing 
after 20 weeks of gestation in previously normotensive women in the 
absence of significant proteinuria. PE was defined as diastolic BP of at 
least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on 
two consecutive occasions more than four hours apart, in combination with 
proteinuria (≥300 mg total protein in a 24-hour urine collection or, if this 
was not available, ≥ +2 proteinuria by dipstick analysis on two consecutive 
occasions at least four hours apart) developing after 20 weeks of gestation 
in previously normotensive women. 
The IUGR was defined as a birth weight below the 5th percentile according 
to standards references for weight based on gestational age [44].
 
Other 
causes of IUGR such as infection, anomalies and abnormal chromosomes 
were excluded in all cases. 
SGA was defined as a birth weight below the 10th percentile but major of 
5th percentile for the gestational age at birth. Also in this group we 
excluded cases with infections, anomalies or abnormal chromosomes. 
For the purposes of the analysis we considered preeclampsia classification 
based on the different etiology: preeclampsia of placental or maternal 
origin. As previously stated, placental PE is associated to impaired fetal 
growth–IUGR, while in preeclampsia of maternal origin the fetal growth is 
appropriate for gestational age, independently of gestational age at 
diagnosis. 
 
Statistical analysis 
Patients were classified accordingly to pregnancy outcome: 
• control group: uneventful pregnancy with normal fetal and maternal 
outcome; 
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• women that developed preeclampsia divided in two subgroups: of 
placental or maternal origin; 
• Isolated fetal growth disorders: IUGR or SGA. 
We compared demographic characteristics, hemodynamic parameters and 
placental parameters among preeclampsia group and controls and among 
growth restriction fetus group and controls. Therefore, we compared 
placental and maternal preeclampsia for hemodynamic and placental 
parameters. The same for SGA and IUGR group. Otherwise, we compared 
placental and maternal preeclampsia each other and also SGA and IUGR. 
Data were expressed as mean ± standard deviation or as median and 
interquartile range for normally and non-normally distributed data, 
respectively. 
Comparisons between groups were performed using t-test or chi-square test 
for numerical and categorical data, respectively. 
For comparison of all groups, one-way analysis of variance (ANOVA) with 
Dunnett’s post-hoc test was used. 
Data were analyzed using IBM SPSS Statistics 19.0.  
Results were considered statistically significant for p <0.05. 
 
RESULTS 
 
Between January 2011 and December 2011, 687 pregnant women were 
recruited in occasion of their Down screening ultrasound examination. At 
the moment of the analysis, 326 pregnancies were still on-going, 26 
patients were lost to follow-up, while 27 patients were excluded because of 
incomplete data acquisition: failed tonometer analysis (12women) and 
failed uterine Doppler Velocimetry evaluation (15 women). This resulted in 
the cohort of 311 women with complete outcome follow-up, of which two 
women had second trimester miscarriage, while one women performed a 
termination of pregnancy for fetal abnormality; these three patients were 
excluded from analysis. 
As showed in Table 1 from the cohort of 308 women that was analyzed, 
eight women developed (2,6%) preeclampsia: of which four were of 
placental origin (PE+IUGR), while remaining four of maternal origin 
(PE+AGA). Seven women developed gestational hypertension (GH) and in 
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all cases the fetus presented appropriate growth for gestational age. 
Therefore, they were included in maternal preeclampsia group (PE+AGA).  
Sixteen pregnancies (5,2%) were complicated by intrauterine growth 
restriction (IUGR), eight (2,6%) had small for gestational age newborns 
(SGA) and finally 269 (87%) women had normal outcome of pregnancy 
and were considered as controls. 
Table 1 reports the maternal or fetal outcomes and complications occurred 
in the study groups.  
 
OUTCOME IN THE STUDY GROUP  308  
PLACENTAL PE (PE+IUGR)  4/308 (1,3%)  
MATERNAL PE (GH/PE+AGA)  4+7=11/308 (3,6%)  
IUGR (Birthweight < 5° pcle)  16/308 (5,2%)  
SGA (Birthweight < 10° pcle and > 5° pcle  8/308 (2,6%)  
COMPLICATION OCCURRED IN THE STUDY GROUP  17/308 (5,5%) 
INTRAUTERINE DEATH  1/308 (0,3%)  
ABRUPTIO PLACENTA  2/308 (0,6%)  
ADMITTANCE TO NICU  11/308 (3,6%)  
PERINATAL DEATH  2/308 (0,6%)  
 
Table 1: Main maternal and fetal/neonatal complications subsequently 
developed in the study group. 
 
The intrauterine death occurred in a first pregnancy woman at 38 weeks of 
gestation with a fetus had a birth weight < 3° pcle. Two cases of placental 
abruptio occurred during labour; in one case associated with gestational 
hypertension. 
One case of perinatal death occurred in a premature newborn at 24,5 weeks 
of delivery with sepsis. The other one in another premature infant at 28 
weeks of delivery with a congenital cardiac anomaly. Finally of the 11 
newborn admittance to NICU, five were premature, two presented a 
pulmonary distress, three were IUGR and the last one had hypoglycemia. 
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Demographic variables into groups 
Table 2A and 2B show the main features of the control group and 
preeclampsia group of maternal and placental origin.  
There were no statistically significant differences in age, ethnicity, parity, 
smoking habit, family history of hypertension, gestational age (GA) and 
CRL at recruitment and sex, between controls and subjects who developed 
maternal or placental preeclampsia.  
Patients with maternal PE showed a statistically higher BMI compared to 
controls (p=0,011), while placental PE showed a higher incidence of 
previous pregnancy affected by preeclampsia (p=0,004). Both maternal and 
placental PE group delivered at an earlier GA, but only placental PE had 
smaller babies and major incidence of admittance to NICU (p< 0,001). 27% 
of women that developed maternal PE applied to IVF (p< 0,001). 
When comparing placental to maternal PE, differences for gestational age 
at delivery, birth weight and admittance to NICU were noticed (p< 0,001). 
 
VARIABLE CONTROLS MATERNAL PE p value PLACENTAL PE p value 
MATERNAL AGE (years) 32,2±11,2 32,2±3,2 0,98 32,7±4,9 0,92 
MATERNAL BMI (Kg/m²) 22,54±3,5 25,3±4,2 0,011 23,3±2,8 0,66 
ETHNICITY 96% 100% 0,5 100% 0,68 
NULLIPARITY 71% 73% 0,92 75% 0,87 
SMOKING 7,8% 0% 0,34 0% 0,56 
CONCEPTION (spontaneus) 
95% 73% < 0,001 100% 0,88 
FAMILY HYPERTENSION 37% 36% 0,97 50% 0,59 
PREVIOUS PE 2,2% 9,1% 0,15 25% 0,004 
GA AT RECRUITMENT (w) 12,3±0,5 12,2±0,5 0,56 12,1±0,5 0,53 
CRL AT RECRUITMENT 59,9±7,0 58,3±5,5 0,47 59±4,5 0,81 
        Table 2A: Demographic characteristics of the study population 
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VARIABLE CONTROLS MATERNAL PE PLACENTAL PE 
GA AT DELIVERY (w) 39,6±1,7 38,3±1,6 33,7±5,1 
BIRTHWEIGHT (g) 3380±450 3118±490 1680±850 
NICU 1,9% 9,1% 75% 
SEX                           M 
                                  F  
47,8% 
52,2% 
45,5% 
54,5% 
50% 
50% 
 
Table 2B: Neonatal characteristics of the study population 
 
Table 3 shows the main features of the control, SGA and IUGR groups. 
There were no significant differences in baseline characteristics. Birth 
weight and gestation at delivery were statistically lower in women with 
IUGR or SGA compared with controls. Only IUGR group presented a 
higher prevalence to admittance to NICU (p=0,048). 
The gestational age and CRL at recruitment were smaller than controls in 
IUGR and SGA group, but statistical significant only for IUGR (p< 0,001). 
The IUGR group differ from SGA only for the percentage of babies 
admittance to NICU (p=0,05). 
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VARIABLE CONTROLS SGA p value IUGR p value 
MATERNAL AGE (years) 32,2±11,2 32,5±3,9 0,95 29,9±4,3 0,074 
MATERNAL BMI (kg/m²) 22,54±3,5 20,2±2,9 0,07 22,9±6,0 0,78 
ETHNICITY : caucasian or 
asian or afro-caribbean 
96% 
4% 
100% 
0% 
0,56 94% 
6% 
0,64 
NULLIPARITY 71% 87,5% 0,32 87% 0,16 
SMOKING 7,8% 12,5% 0,63 0% 0,25 
CONCEPTION (spontaneus) 95% 100% 0,78 100% 0,61 
FAMILY  HYPERTENSION 37% 37,5% 0,97 56% 0,12 
PREVIOUS PE 2,2% 0% 0,67 6,3% 0,31 
GA AT RECRUITMENT (w) 12,3±0,5 12,2±0,5 0,67 11,9±0,3 < 0,001 
CRL AT RECRUITMENT  59,9±7,0 55,5±4,1 0,10 55,1±3,9 < 0,001 
GA AT DELIVERY (w) 39,6±1,7 38,4±0,7 0,048 38,2±1,9 0,002 
BIRTHWEIGHT (g) 3380±450 2633±65 < 0,001 2390±294 < 0,001 
NICU 1,9% 0% 0,58 12,5% 0,048 
SEX                                M 
                                       F 
47,8% 
52,2% 
25% 
75% 
0,18 38% 
62% 
0,37 
 
Table 3: Demographic characteristics of growth restriction groups 
 
Hemodynamic characteristics: 
The hemodynamic parameters for preclamptic groups are given in Table 4 
A. 
There were no significant differences in heart rate and Augmentation index 
at 75 bpm between the two groups of PE compared with controls and also 
between each other (Figure 3). 
Mean arterial pressure was significantly higher in both placental and 
maternal preeclampsia when compared to the control group (Figure 1), 
while central systolic pressure was significantly higher only in placental PE 
group (p< 0,001) (Figure 2). 
27 
 
Table 4 B shows the comparison between the hemodynamic parameters in 
IUGR, SGA and controls. There were no statistically significant differences 
between groups (Figure 4). 
 
VARIABLE  CONTROLS  MATERNAL PE  p VALUE  PLACENTAL PE  p VALUE  
MEAN ARTERIAL 
PRESSURE (mmHg) 
77,7±8,4 85,8±12,4 0,002 87,5±12,6 0,02 
HEART RATE (bpm) 79,2±11 83,4±9,4 0,25 77,5±8,0 0,72 
CENTRAL SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
92,3±9,4 101,4±16,6 0,076 107±21,3 < 0,001 
AUGMENTATIONE 
INDEX (%) AT 75 
bpm 
16,14±11 19±11,2 0,36 21,75±14,6 0,29 
Table 4 A: Maternal haemodynamic and vascular characteristics of the PE 
group 
 
VARIABLE  CONTROLS  SGA  p VALUE  IUGR  p VALUE  
MEAN ARTERIAL 
PRESSURE  
77,7±8,4 76,7±8,4 0,73 78,7±11,2 0,62 
HEART RATE  79,2±11 77,4±8,9 0,60 75,9±11,1 0,21 
CENTRAL 
SYSTOLIC BP  
92,3±9,4 88,5±11 0,41 93,7±12,9 0,44 
AUGMENTATION 
INDEX (%) AT 75  
16,14±10,8 17,5±7,6 0,68 18,7±13 0,33 
Table 4 B: Maternal haemodynamic and vascular characteristics of the SGA 
and IUGR group 
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Fig. 1: Boxplots of Mean arterial pressure in preeclampsia of placental or 
maternal origin and controls. 
 
 
Fig. 2: Boxplots of Central systolic blood pressure in preeclampsia of 
placental or maternal origin and controls. 
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Fig. 3: Boxplots of Augmentation index at 75 bpm in preeclamptic groups 
and controls 
 
 
Fig. 4: Boxplots of Augmentation index at 75 bpm in growth restriction 
groups 
 
Placental parameters: 
The results of the Doppler examination of the uterine arteries are 
represented in Table 5 for preeclampsia groups. 
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The mean uterine artery PI was significantly higher in placental PE group 
(p< 0,001) when compared with the other groups (Figure 6). Furthermore, 
in preeclampsia of placental origin, 50% of women presented abnormal 
uterine artery PI (> 95° pcle) as soon as in first trimester in comparison 
with only 9% in preeclampsia of maternal origin (p< 0,001 vs p=0,42) 
(Table 5). 
Maternal serum PAPP-A, which is known to be altered in pregnancies that 
subsequently develop PE, was significantly lower only in maternal PE 
group (p=0,024). 
IUGR group presented, similarly to placental PE group, a mean uterine 
artery PI higher than controls and SGA group (p< 0,001) (Table 6). 
 
VARIABLE CONTROLS MATERNAL PE p value PLACENTAL PE p value 
MEAN UTERINE 
ARTERY PI 
1,5±0,5 1,4±0,7 0,30 2,5±0,5 < 0,001 
ABNORMAL 
UtA 
5% 9% 0,42 50% < 0,001 
MOMM PAPP-A 0,94±0,6 0,58±0,2 0,024 0,77±0,3 0,52 
 
Table 5: Placental paramethers of study population in preeclapsia groups. 
 
VARIABLE SGA p value IUGR p value 
MEAN UTERINE 
ARTERY PI 
1,4±0,6 0,70 1,8±0,5 0,032 
ABNORMAL UtA 12,5% 0,25 19% 0,008 
MOMM PAPP-A 0,98±0,4 0,89 0,74±1 0,16 
 
Table 6: Placental paramethers in IUGR, SGA and controls. 
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Fig. 5: Boxplots of Mean uterine artery PI in preeclampsia of 
placental or maternal origin versus controls. 
 
 
Fig. 6: Boxplots of Mean uterine artery PI in growth restriction 
fetuses 
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DISCUSSION 
 
The aim of the current study was to investigate the maternal cardiovascular 
adaptation and in particular arterial stiffness in women destined to develop 
PE and IUGR. Furthermore, we adopted a new classification of PE based 
on the underlying etiology: PE of placental origin when associated to IUGR 
and maternal when the fetal growth appears within normal ranges, 
independently of gestational age at the diagnosis. 
Placental and maternal preeclampsia recognize different etiologies and, 
therefore, develop through different models of maternal cardiovascular 
adaptation in the latent phase of the disease. In the same way, IUGR and 
SGA fetuses present different etiologies. 
Accurate prediction of preeclampsia and intrauterine growth restriction is 
crucial to allow judicious allocation of resources for monitoring and the 
development of preventive treatment to improve maternal and perinatal 
outcomes.  
Early identification of women at risk of pre-eclampsia facilitates targeted 
surveillance and intervention [114-115]. There are likely to be significant 
advantages in predicting preeclampsia in the first, as opposed to the second 
trimester; given that the disease process is already established by the mid 
second trimester, it seems likely that any successful preventative measure 
will need to be instituted as early in pregnancy as possible. 
Because the incidence rates of preeclampsia and IUGR are relatively low 
(1.3–6.7% in developing and 0.4–2.8% in industrialized countries) [116], 
any screening tests will need to have high levels of both sensitivity and 
specificity. Currently, none of the measurements in the first trimester meets 
these criteria. While different measures of placental dysfunction have been 
associated with increased risk adverse pregnancy outcomes, the ability of 
any single one to accurately predict these outcomes is poor. Attempts to use 
predictive models combining analytes and measurements of placental 
structure and blood flow have so far produced mixed results. The use of 
first trimester biochemical markers in combination with uterine artery 
Doppler screening shows promise as potential screening tools. 
Improvement in ultrasound technology provides potentially useful novel 
tools for evaluating placental structure, but measurements need to be 
standardized in order to be useful. One potential area, in the first trimester, 
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that is yet few explored is the valuation of central hemodynamic and 
arterial stiffness by pulse wave analysis. 
 
Maternal factors 
Among the maternal factors that may contribute to the development of 
maternal PE, body mass index and conception by IVF seem to play an 
important role. In our study maternal PE showed the highest values of BMI 
and the highest percentage of IVF conceived pregnancies; both factors 
known to be well related to metabolic syndrome, low grade chronic 
inflammation and insulin resistance.  
Conversely, placental PE showed the highest number of women with 
reoccurrence of preeclampsia that supports the presence of immune/genetic 
predisposition.  
It is interesting to observe that the BMI of women with SGA babies is 
higher when compared to controls and IUGR group, suggesting a possible 
similar etiology to maternal PE.  
 
Uterine artery 
Doppler studies suggest that preterm preeclampsia/IUGR is associated with 
defective invasion of the spiral arteries, whereas the spiral artery defect 
plays a much smaller role in the cases nearer term [117]. Thus, term 
preeclampsia/IUGR seem to be associated with normal trophoblast 
transformation in the first trimester, and late atherosclerotic changes in 
spiral arterioles. Such late changes may be the consequence of increased 
placental mass, as occurs in diabetic and twin pregnancies, related to the 
senescence of the placenta in prolonged pregnancy or as a result of 
placental edema and necrosis in fetal hydrops [32,118].  
Abnormal uterine artery Doppler studies in the first trimester have been 
shown to be associated with preeclampsia/IUGR. Gomez et al. reported 
that the sequence of changes in uterine artery Dopplers between the first 
(11 and 14 weeks) and second (20 and 24 weeks) trimesters correlates with 
the subsequent development of preeclampsia and IUGR [119].  
The detection rate of uterine artery screening for preeclampsia or IUGR at 
any gestation is better for severe than for mild disease. Increased resistance 
indices in the first trimester are particularly effective in identifying preterm, 
rather than term, preeclampsia [120-122]. 
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On the other hand, Martin et al. (2001) reported that uterine Doppler PI at 
11–14 weeks had a disappointing sensitivity of 11.7% for all IUGR, but for 
IUGR requiring delivery by 32 weeks sensitivity increased to 27.8% [110]. 
This disparity may result from the distinction between the pathophysiology 
of preterm and term preeclampsia/IUGR discussed earlier or from the 
different methodologic approaches used in the different studies. In addition, 
uterine artery Doppler in the first and the second trimesters was shown to 
have a remarkably higher sensitivity in women with preeclampsia 
complicated by small-for-gestational-age (SGA) babies compared with 
uncomplicated preeclampsia or SGA alone [123]. 
Our study are in accordance with the literature data and showed that the 
mean uterine artery PI was significantly higher in women who 
subsequently developed placental PE or IUGR, but not in maternal PE and 
SGA, confirming indirectly our hypothesis that maternal PE is not 
associated with impaired placentation. 
Moreover, after dividing the uterine artery in two groups: normal and 
pathological according to the PI value (PI>2,3) [110], half of women in 
placental PE group presented pathological uterine artery PI in comparison 
to only nine percent in maternal PE group.  
 
PAPP-A 
PAPP-A is an insulin-like growth factor binding protein (IGFBP) protease 
with specificity for IGFBP 2 and 4. Reduced levels of PAPP-A may result 
in increased amounts of insulin-like growth factor (IGF) being bound to its 
carrier proteins and hence not available at the cell receptor level to 
stimulate fetal growth and trophoblast invasion of the decidua [124]. Many 
studies have reported reduced maternal serum PAPP-A concentration at 
11–14 weeks and increased risk for subsequent development of 
preeclampsia, SGA and preterm delivery [125-127].  
For IUGR, the sensitivity of PAPP-A below 5
 
th percentile in the first 
trimester were 8–33% [125-127]. 
Our data show that MOMM PAPP-A was significantly lower only in 
maternal PE group, thus indicating, probably, its association with metabolic 
syndrome. 
Our assumption is supported by Sifakis et al [128] that in 2011 has 
demonstrated that at 11–13 weeks’ gestation in pregnancies destined to 
develop PE compared with unaffected controls, the median maternal serum 
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IGFBP-3 and uterine artery PI were higher and serum PAPP-A was lower. 
Evidence from both in vitro and in vivo studies suggested that increased 
levels of IGFBP-3 are associated with hyperglycaemia, metabolic 
syndrome and increased insulin resistance [129-135]. 
In women destined to develop late PE, placental perfusion and fetal growth 
are often normal and the main pathophysiological processes resemble those 
of the metabolic syndrome with an increase in adipose tissue, impaired 
glucose tolerance and increased insulin resistance [40-43]. In non-pregnant 
women, insulin is the main regulator of IGFBP-1, and studies in pregnancy 
reported that IGFBPI production by the decidualized stroma is inhibited by 
insulin [136,137]. Always in 2011, Sifakis et al [138] wrote that the low 
levels of IGFBP-1 in women destined to develop PE may be the 
consequence of the associated hyperinsulinemia and increased insulin 
resistance [139,140]. 
 
Haemodinamic parameters 
Pregnancy is associated with major hemodynamic changes such as 
increased cardiac output and heart rate and the presence of placental 
fistulae. 
There is a marked increase in vascular compliance in normal pregnancy so 
as to accommodate the major cardiovascular changes taking place within 
the mother as a whole and within the uterus in particular. 
Previous studies have demonstrated that, in normal pregnancy, aortic 
compliance increases in response to increased levels of estrogen, mediated 
by increased circulating nitric oxide levels: resistance remains low until 
delivery [102]. 
We know that there is little or no difference in vascular compliance 
between women with established preeclampsia and nonpregnant women. 
The pulse wave analisys (PWA) has been shown in nonpregnant 
individuals to accurately evaluate arterial stiffness in cardiovascular 
disorders. Preeclampsia is a disorder of vascular endothelium, and recent 
studies have shown that PWA can successfully assess the increased arterial 
stiffness that results [99,141]. 
In recent years, it has been shown that serum and placental levels of 
angiogenic factors such as sFlt1 and soluble endoglin are altered in women 
with preeclampsia not just at the time of the clinical manifestations of the 
disease but often many weeks prior its clinical onset [76,142,143]. This led 
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us to hypothesise that the increase in arterial stiffness might occur in 
advance of the clinical disease, that this might be measurable using arterial 
PWA and that, if so, these observations might allow us to identify early 
those women who subsequently developed preeclampsia and IUGR.  
Each heartbeat generates a pulse wave that travels away from the heart. 
This waveform is reflected from bifurcations within the arterial tree and 
from the junctions of the preresistance and resistance vessels [87-89]. The 
reflected wave travels back toward the heart and meets the advancing 
wave, augmenting its height (Fig. 1A). Generally, the reflected wave 
reaches the aorta during diastole, boosting the height of the diastolic 
portion of the wave. This also helps to maintain coronary artery perfusion. 
When arterial wall stiffness is increased (as in hypertensive disorders of 
pregnancy) the arterial pulse wave travels faster, so the reflected wave 
reaches the advancing wave in systole, resulting in significant 
augmentation of the systolic peak (Fig. 1B). This can be measured as raise 
augmentation index. 
Previous studies, in women with established PE have revealed inconsistent 
results, which could be due to the lack of number of women with severe 
PE, we establish that PE is characterized by increased arterial stiffness.  
Some of them, assessing the arterial stiffness of other vascular pathways 
such as base of the aorta to popliteal artery [99] and abdominal aorta [83] , 
have also confirmed increased arterial stiffness in women with established 
PE by pulse wave velocity (PVW).  
The findings of this study demonstrate that in women destined to develop 
PE, during the second or third trimester of pregnancy, there is not an 
increase in maternal arterial stiffness as assessed by pulse way analysis. 
The Augmentation index at 75 bpm values were similar to the 
normotensive group and in the women who developed preeclampsia, both 
placental or maternal type and also in women that developed IUGR or SGA 
fetuses. 
This is compatible with the results of previous study of Kaihura et al 
[100].that showed, in women with established PE, there was an increase in 
pulse way velocity but not in Augmentation index. However, it is in 
contrast with a study by Khalil et al [127] that suggested that AIx could be 
used as a first trimester predictor of PE. In this study is important observed 
that about 14 cases of preeclampsia, 8 were early preeclampsia. 
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AIx refers to the difference between the second and first systolic peaks, 
expressed as a percentage of the aortic pulse pressure. When compared 
with normotensive women, women with established PE had higher first 
systolic peak, which provides an estimate for stroke volume, higher second 
systolic peak, and shorter aortic Tr ( time to reach the reflected wave). 
Furthermore, AIx depends on the intensity of the reflected wave, and, as 
such, it will depend on the diameter and elasticity of the small muscular 
arteries/arterioles at the major sites of pressure wave reflection. Therefore, 
alterations in muscular smooth muscle tone affecting mainly the small 
muscular arteries but not the elastic aorta might influence reflected wave 
intensity and hence Aix just in the first trimester of pregnancy. 
In addition to increased arterial stiffness, women who subsequently 
developed PE demonstrated increased peripheral and central BP. Studies in 
non-pregnant hypertensive patients have shown that central and peripheral 
BP are not synonymous and antihypertensive agents can exert differential 
effects on the two types of BP [128]. In patients with end-stage renal 
disease, central aortic pulse pressure was of greater predictive value for 
cardiovascular outcomes than brachial pulse pressure [129,130]. 
Previous studies assessing peripheral BP have reported that in women 
destined to develop PE, the BP is higher than in the non PE group both 
during the second but also in the first-trimester of pregnancy [130]. It 
would be interesting to investigate the extent to which the prediction of PE 
can be improved by the measurement of central rather than peripheral BP 
[131-133]. 
Our data showed that the mean arterial pressure was significantly higher in 
both placental and maternal preeclampsia compared with the control group, 
but central systolic pressure was statistical significant only in placental PE 
group. In conclusion, we can hypothesize that PE is associated with 
increased maternal central pressures, but not altered wave reflection, 
suggesting that maternal large artery stiffness in this population is 
increased compared with women with uncomplicated pregnancies, also if is 
not possible register with PWA. 
As expected, the hemodynamic characteristics between normotensive 
pregnancies affected by IUGR or SGA were no significant differences for 
all hemodynamic parameters between groups and controls. 
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Limits of the study 
We acknowledge that the number of participants in the study is too small to 
draw firm conclusions, and confirmation from larger studies will be 
required. 
The outcomes derived for about 60% from telephone interview and not 
always from clinical sheet. 
Finally the diagnosis of IUGR is based on birth weight and not on fetal 
ultrasound evaluation and Doppler velocimetry. 
 
      CONCLUSION 
 
Although, the classification of preeclampsia based on time domain, at the 
moment the most used, brought to some improvements in terms of 
biochemical and biophysical tests prediction, at present is still not able to 
fulfill all diagnostic and preventive needs. Indeed, despite all scientific 
effort for the past three decades, at the present there does not exist 
universally recognized screening test of any kind capable to predict 
preeclampsia or IUGR and the severity of the disease.  
With this pilot study, we wanted to investigate the characteristics of 
preeclampsia of maternal and placental origin and pregnancies with fetal 
growth restriction in terms of peripheral and central vascular resistance by 
applanation tonometry in the first trimester of pregnancy. Due to the 
smallness of the cohort, we did not try to assess the prediction of the test. 
Nevertheless, the newness of our work stand in the understanding of the 
underlying physiopathology of preeclampsia. 
Our data confirmed the hypothesis regarding different origin of PE: indeed, 
in PE of maternal origin we found the highest BMI and the highest 
percentage of IVF-pregnancies. Both this factors are well known to 
correlate to metabolic syndrome, low grade chronic inflammation and 
insulin resistance. 
Conversely, in PE of placental origin we found the highest number of 
women with reoccurrence of preeclampsia that supports the 
immunological/genetic hypothesis that causes inadequate placentation. This 
hypothesis is supported also by the observation that women with 
preeclampsia of placental origin present significantly higher mean uterine 
artery PI, sign of an impaired placentation as soon as in the first trimester 
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of pregnancy. A further confirmation of a poor placentation derives from 
the presence of the highest percentage of babies admittance to NICU in 
preeclampsia of placental origin and IUGR group. 
As it concern the hemodynamic parameters, in accordance to the literature, 
we found the mean arterial pressure significantly higher in both 
preeclampsia of placental and maternal origin when compared to the 
control group. Interestingly, the central pressure, both systolic and 
diastolic, was significantly higher only in placental PE group suggesting 
lower central vascular compliance in women with inadequate placentation. 
This could suggest a different and more severe physiopatological pathway 
at the basis of preeclampsia of placental origin when compared to maternal 
one. 
Several Authors found increased values of augmentation index in women 
with preeclampsia (more pronounced in early and less important in late PE) 
at the time of onset of the disease. Conversely, we found no significant 
differences in Augmentation index at 75 bpm between groups, suggesting 
that in the first trimester the biochemical and hormonal modifications still 
does not reflect on peripheral vascular resistance both in preeclampsia of 
maternal and placental origin. 
In conclusion, we found that the classification of preeclampsia based on its 
origin, maternal and placental, is supported by the demographic data. Our 
data suggest that, as soon as in first trimester, for arterial mean pressure 
been equal in both women that will develop PE of maternal and placental 
origin, and higher in respect to controls, only PE of placental origin 
presents higher central pressure. Nevertheless, no differences were found 
for wave reflection, suggesting later development of the peripheral vascular 
alteration.  
Future studies should also aim at improving our knowledge of the 
biological mechanisms to understood the pathofisiology of placental 
pathology resulting in the changes seen in IUGR and placental 
preeclampsia and mechanisms on basis of maternal preeclampsia and SGA. 
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